Evidence map›Paper›PMID 39220798›Full record

ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2024

Hepatocyte-Specific

Caige Li, Yu Xue, Yiwei Liu, Kangning Zheng, Yuting Gao, Yi Gong, Junlan Lu, Yuman Zhang, Jingmin Ji, Zhiqin Zhang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Caige LiDepartment of Pathobiology and Immunology, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, People's Republic of China.
Yu XueDepartment of Pathobiology and Immunology, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, People's Republic of China.
Yiwei LiuDepartment of Pathobiology and Immunology, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, People's Republic of China.
Kangning ZhengDepartment of Pathobiology and Immunology, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, People's Republic of China.
Yuting GaoDepartment of Pathobiology and Immunology, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, People's Republic of China.
Yi GongDepartment of Pathobiology and Immunology, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, People's Republic of China.
Junlan LuDepartment of Pathobiology and Immunology, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, People's Republic of China.
Yuman ZhangDepartment of Pathobiology and Immunology, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, People's Republic of China.
Jingmin JiDepartment of Pathobiology and Immunology, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, People's Republic of China.
Zhiqin ZhangDepartment of Pathobiology and Immunology, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, People's Republic of China.
Xinli ShiDepartment of Pathobiology and Immunology, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Yes-associated protein 1 (YAP1) is a crucial molecule in the Hippo pathway. The impact of hepatocyte-specific Methods: Three-week-old Results: Conclusion:

Indexed as

hepatocyte-specific Yap1 knockoutlipidomicperilipin-2triglycerideyes-associated protein

Identifiers

PMID39220798
PMCPMC11365535

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.